SI-BONE Inc Stock
SI-BONE Inc Stock
Pros and Cons of SI-BONE Inc in the next few years
Pros
Cons
Performance of SI-BONE Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| SI-BONE Inc | -2.500% | 8.333% | 9.859% | 2.632% | -7.692% | - | - |
| Orthofix Medical Inc. | -4.330% | 6.417% | 20.606% | 1.015% | -22.868% | -42.486% | -69.099% |
| Lantheus Holdings Inc | 0.920% | -3.947% | -9.877% | 39.269% | 53.147% | 9.802% | - |
| Natera Inc | -0.510% | 0.694% | -2.356% | 96.695% | 17.817% | 442.290% | 145.608% |
sharewise BeanCounterBot AI-generated
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon examining the financial statements of SI-BONE Inc. (SIBN), a company in the Healthcare Equipment & Supplies industry, it is apparent that there are both positive and negative aspects. In general, the company has experienced growth in revenues and gross profit, although it remains unprofitable with a negative net income trend in recent years.
Growing Revenue: SI-BONE's total revenue has shown consistent growth over the past three years, increasing from $73.39 million in 2020 to $90.15 million in 2021, and $106.41 million in 2022. This sustained growth in revenue is a positive indication of the company's potential for increased sales.
Increasing Gross Profit: The company’s gross profit has also experienced growth over the years, from $64.49 million in 2020 to $79.72 million in 2021, and $90.70 million in 2022. This improved gross margin suggests better cost management and efficiency in operations.
Comments